Abstract The role of insulin in the treatment of acute coronary syndrome (ACS) has been widely studied over the past 100 years. The current indication for its use in this context is the treatment of hyperglycemia, irrespective of diabetes, which is associated with adverse outcome. Initial theories proposed that glucose was beneficial in the context of myocardial ischemia and insulin was required to enable glucose cell uptake. However, studies testing this hypothesis with routine insulin administration during ACS have produced disappointing results and research interest has therefore declined. We propose that the less well known but important vasodilator effect of insulin has been overlooked by some of these studies and warrants further consideration. Previous reports have shown that hyperinsulinemic euglycaemia improves myocardial blood flow reserve. With this in mind, this review considers the role of insulin in the context of ACS from the perspective of a vasodilator rather than a metabolic modulator. We discuss the importance of time to treatment, dosage of insulin administered, problems with hypoglycaemia and insulin resistance, and how they may have affected the outcomes of the major trials. Finally, we propose new study designs that allow determination of the optimal vasodilator conditions for the use of insulin as adjunctive pharmacotherapy during myocardial ischaemia.
Introduction
Hypo-and hyperglycemia (dysglycaemia) are common in acute coronary syndrome (ACS), and as such, improvement in blood glucose has been extensively studied as a potential therapeutic target. The current role of insulin therapy at the time of ACS is the regulation of blood glucose. This was consequent to the publication of the DIGAMI trial in 1997 which concluded that maintaining euglycaemia improved outcome [1] . However the majority of subsequent large-scale multi-centre trials employing strategies with much tighter blood glucose control and involving over 25,000 patients in total, have generally failed to demonstrate any clinical benefit. The reasons for this are unclear but several theories, including the occurrence of hypoglycemia and hyperglycemia, have been suggested [2] [3] [4] [5] .
Trials utilising insulin in ACS have their basis centred around two beneficial mechanisms. Firstly, the addition of glucose, insulin, and potassium (GIK) therapy is believed to optimise fuel conditions for the heart and prevent arrhythmia during myocardial ischaemia [6] . Secondly, the regulation of blood glucose during myocardial ischemia in the form of intense insulin therapy (IIT) could prevent the detrimental effects of dysglycaemia. Our group demonstrated that an intravenous insulin infusion increases peak myocardial blood flow (MBF) by up to 30 % [7] . Intuitively, in the setting of ACS, the vasodilator aspect of insulin should be beneficial as a form of adjunctive reperfusion therapy particularly in the immediate time period following primary angioplasty for STEMI. Insulin may also be helpful in mitigating the effects of the 'no-reflow' phenomenon which occurs in up to 50 % of patients undergoing primary percutaneous coronary intervention (PCI) [8] . In the setting of NSTEMI, insulin's vasodilator effect may reduce ischemia by either increasing flow down the partially obstructed culprit vessel or by enhancing collateral flow. We therefore suggest consideration be given as to whether insulin's vasodilator rather than metabolic action has an important role to play in the context of myocardial ischemia [9, 10] . The potent vasodilator effect of insulin on the myocardial vasculature is well described in the literature, yet this action is rarely credited as being of potential mechanistic benefit in the setting of ACS-related GIK and IIT studies [11] [12] [13] . Previous IIT and GIK trials were purposefully designed to exploit the metabolic benefits of insulin rather than its effect on microvascular function. This biochemically orientated approach could explain the negative outcomes in previous insulin-based ACS studies. If we accept the premise that insulin has a role as adjunctive reperfusion therapy then several aspects in trial design such as time to treatment and dosage, could have important mitigating effects.
This review considers the role of insulin in the context of acute coronary syndromes from the perspective of a vasodilator rather than metabolic action.
Methodology
We performed a systematic search (using PUBMED, EMBASE, Cochrane Central Register of Controlled Trials CENTRAL, and Google Scholar) for randomised trials and review articles from 1960 to November 2015 of the English literature regarding the use of insulin in ACS, and insulin's effect on myocardial blood flow. In order to identify and retrieve all potentially relevant articles regarding this topic, the search was performed utilizing the terms 'insulin', 'myocardial blood flow', 'myocardial infarction', 'coronary flow reserve' and 'acute coronary syndrome'. Articles perceived to be relevant to insulin use in ACS were selected for review. References of the studies could also be included in the analysis.
Glucose-Insulin-Potassium Infusions during Acute Coronary Syndromes
Metabolic modulation of acute myocardial infarction with glucose-insulin-potassium (GIK) infusion was originally proposed in the 1960's [14] . The concept is attractive because the therapy is simple, low cost and easily implemented. GIK infusions were thought to be potentially beneficial through several different mechanisms. Free fatty acids are normally the primary fuel source for the heart but are toxic to the myocardium in the ischemic setting causing sarcolemmal and mitochondrial membrane disruption [15] . Exogenous insulin was known to suppress circulating levels of free fatty acids and also prevent their uptake by the myocardium [15] [16] [17] . Provision of high-dose glucose was thought to improve the efficiency of myocardial energy production during acute ischemia by becoming the preferred fuel source for the heart. Intracellular levels of potassium are depleted during ischemia and therefore the provision of exogenous potassium to increase levels within the myocyte were believed to raise the threshold for ventricular arrhythmias [18, 19] . An overview by Fath-Ordoubadi in 1997 resulted in a revival of interest in GIK administration for treating acute myocardial infarction (AMI) [20] . The first study in the post-thrombolytic era to investigate this concept was the ECLA-GIK pilot trial in 1998 [21] . This study randomised patients with suspected AMI to low or high dose GIK following admission. They found that there was a significant 66 % reduction in mortality in those patients who received both high-dose GIK and reperfusion strategies compared to reperfusion alone. Importantly, this difference was driven by an unexpectedly high mortality rate in the control arm (15 %), which the authors attributed to the small cohort. Nonetheless this re-stimulated great interest in GIK therapy in ACS and a further 10 trials have taken place since, one study did not reach completion, and another was an analysis of two studies combined (see Tables 1 and 2 ). Study design varied considerably with regards to insulin infusion dosage and regulation of blood glucose parameters. Overall, a total of 26,855 patients have been recruited with studies ranging from the small (120 patients) to the very large (over 20,000). The results have been disappointingly conflicting. Two studies have shown a benefit in primary end-point with evidence in favour of GIK (total 525 patients) [21, 22] , seven showed no difference (25,496 patients) [23] [24] [25] [26] [27] [28] [29] , and one showed increased harm (954 patients) [30] .
Intensive Insulin Therapy during Acute Coronary Syndromes
Several studies have demonstrated that in-patient hyperglycemia is associated with a significant increase in mortality in ACS. It was therefore thought that improved glycemic control Median (IQR) 1.5 (1, 3) in ACS would relate to improved outcomes. The Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) was the first study to investigate this hypothesis [1] . This study randomised patients with DM presenting with an AMI to receive either intensive insulin therapy (IIT) or conventional treatment for hyperglycemia. After 1-year, a significant 29 % relative risk reduction in all-cause mortality was observed with IIT. As a result of this landmark study, national guidelines were changed recommending that IIT should be used to control elevated blood glucose in those patients presenting with ACS and hyperglycemia. Insulinbased glycemic control for patients following ACS is now widespread and common practice in the Western world [31] .
In line with this thinking, subsequent studies were undertaken to examine whether a narrower range of glucose control would translate into lower mortality rates. Three separate studies involving almost a total of 1800 patients have since been undertaken ( Tables 1 and 2 ) [32] [33] [34] . The method of IIT differed significantly between studies: HI-5 regulated blood glucose between 4 and 10 mmol, DIGAMI-2 opted for ongoing glucose regulation using subcutaneous insulin following intravenous infusion, and RECREATE targeted lower blood glucose during intravenous insulin infusion. However all have failed to show any significant benefit with regard to improved blood glucose control and primary endpoints.
Intensive Insulin Therapy and Glucose-Insulin-Potassium Infusions Lack Efficacy in Acute Coronary Syndromes
Since DIGAMI there have been thirteen clinical trials investigating the effect of GIK infusions and IIT in ACS (Tables 1 and  2) . Apart from three, all have failed to show any convincing significant benefit and two actual harm. The reasons for the failure of these studies to demonstrate clinical benefit is unclear but several theories have been postulated. The foremost is that hypoglycaemia in the insulin-treated groups may be having an adverse effect. Several studies have associated hypoglycaemia (plasma glucose ≤3.9 mmol/l) with an increase in cardiovascular mortality, including those following an ACS [35, 36] . Hypoglycemia, either symptomatic or biochemical, is a frequent occurrence in the insulin arm, ranging from 10 to 22 % (see Tables 1 and 2 for hypoglycemia occurence in studies). Hypoglycemia has been demonstrated to have a number of adverse physiological effects, including the induction of a hypercoagulant state, an inflammatory response, QT prolongation and a detrimental effect on cardiac metabolism because of the inability of the heart to use glucose [37, 38] .
The Effect of Insulin on Myocardial Blood Flow
Myocardial blood flow reserve (MBFR) is the ratio of MBF at peak hyperaemia to that at rest, and, in the context of unobstructed coronary arteries, is a measure of microcirculatory function. Fig.1 ) demonstrated that insulin-induced hypoglycaemia was associated with a 14 % reduction in MBFR with respect to baseline values in both type 1 diabetics and healthy controls [2] . We suggested that the reduction in blood flow occurring during hypoglycaemia might be detrimental in the context of ACS. Importantly, we also noted that hyperinsulinemic euglycemia (insulin infused at 1.5 mU/Kg/min) was associated with a 22 % increase in MBFR above baseline. This increase in myocardial blood flow by hyperinsulinemia had also been observed in other previous human studies. In 1997, Rogers et al. reported a 12 % increase in coronary sinus blood flow in patients with suspected ischaemic heart disease who received a GIK infusion [11] . A further study found that local intracoronary insulin infusion increased coronary sinus blood flow, suggesting a direct insulin-mediated effect [12] . Sundell et al. observed that higher blood insulin levels resulted in greater increases in myocardial blood flow [40] . Despite the potent vasodilator effect of insulin on the myocardial vasculature being well described in the literature, this action is rarely credited as being of potential mechanistic benefit in the setting of ACSrelated GIK and IIT studies. Furthermore, the mechanism by which insulin induces vasodilation is not fully understood but is thought to be mediated through nitric oxide release [12] . Sobrevia performed the first in vitro study to examine this association by monitoring L-arginine transport -a precursor for nitric oxide production -into human umbilical vein endothelial cells (HUVECs) [41] . When HUVECs were incubated with insulin under conditions of euglycaemia (5 mmol/L) there was a 2.5-fold increase in the transport of the amino acid L-arginine (a precursor for nitric oxide production via nitric oxide synthase) into the HUVECs. They also noted a 3-fold increase in intracellular cyclic guanosine monophospate (cGMP) concentrationsan index of nitric oxide synthesis. This data demonstrated that insulin led to an endothelium-dependent release of nitric oxide and this was suggested to be the mechanism behind insulininduced vasodilatation.
Insulin: Vasodilator and Metabolic Actions in Acute Coronary Syndromes
Intuitively, in the setting of ACS, the vasodilator aspect of insulin should be beneficial as a form of adjunctive reperfusion therapy. We must therefore consider whether insulin's vasodilator action also has an important role to play in the context of myocardial ischemia. Previous IIT and GIK trials were designed to exploit the metabolic benefits of insulin rather than its effect on microvascular function. Thus, it is worth re-examining from a reperfusion stand-point, the impact biochemically adopted approach in trial design may have affected outcomes with previous insulin-based ACS studies. Thus, if insulin's vasodilator action is important as adjunctive reperfusion therapy then the following aspects in trial design could have a significant effect:
1. Time delay to initiation of insulin therapy following acute myocardial ischemia. 2. Optimum treatment dose with insulin therapy to achieve maximum vasodilator effect. 3. Prevalence of hypoglycaemia. 4. Role of insulin resistance.
Time Delay to Initiation of Insulin Therapy in IIT and GIK ACS Studies
It is well established that the mortality following AMI is directly related to infarct size. Infarct size is directly related to Fig. 1 Myocardial blood flow reserve (MBFR) at baseline and during hyperinsulinemic euglycemia (HE) and hyperinsulinemic hypoglycemia (HH). In healthy controls HE increases MBFR 22 % above baseline, whereas HH reduces MBFR 14 % below baseline (both p < 0.0001). There was a similar effect in diabetics. Solid circles, healthy control subjects; solid squares, type 1 diabetes mellitus patients (mean ± SD) [7] the area of ischemic myocardium at risk and the duration of ischemia. For the past 40 years, clinical research in reperfusion therapy has been directed towards the development of agents that improve MBF in the most rapid and complete manner possible. This has been achieved with great success using biological clot dissolution (thrombolysis) and has been superseded by mechanical means (primary angioplasty). It is well established that any delay in reperfusion therapy is directly related to an adverse outcome and that 'time is muscle' [42] .
Out of the 14 reports on IIT and GIK, the times from onset of chest pain to administration of IIT and GIK ranged from 55 min to 19 h. In the DIGAMI study, insulin was given 'within 24 h' [1] . Furthermore, because either median or mean values are consistently quoted this means that a significant percentage of patients received insulin therapy beyond that time frame. For example, in the largest study (CREATE-ECLA) of 20,000 patients with ST-elevation myocardial infarction (STEMI), the median time to randomisation was 4.7 h resulting in 20 % of patients receiving GIK 8-12 h after symptom onset [25] . In the REVIVAL study, 25 % of patients received insulin therapy more than 18 h after symptom onset [24] . The IMMEDIATE trial administered fixed-dose GIK infusions out-of-hospital and achieved a median treatment initiation time of 1.3 h after symptom onset [29] . However only 50 % of enrolled patients resulted in a final diagnosis of ACS suggesting that many patients had alternate diagnoses, and this may have inadvertently affected outcome. Nevertheless, in sub-group analysis of the STEMI population, there was a significant reduction in composite outcome of cardiac arrest and 1-year mortality.
Clearly, if insulin therapy is to be successful as an adjunctive reperfusion therapy, treatment needs to be given as quickly as possible and within a minimum timeframe. The wide range of times to treatment in all of the above trials may have had an important confounding effect.
Suboptimal Treatment Dose with Insulin Therapy to Achieve Maximum Vasodilator Effect
The doses of insulin therapy in the GIK and IIT trials varied considerably, with some protocols containing high and low dose arms, and others titrating insulin infusion rates according to blood glucose. Where data was available, the mean insulin infusion rate (in mU/kg/min) for each major trial was calculated and presented in Tables 1 and 2 . Our group demonstrated that 1.5 mU/kg/min insulin is able to increase peak MBF by 30 % compared to without [7] . This dose compares favourably with the findings of Sundell [40] . These investigators showed that an insulin infusion of 1.0 mU/kg/min and 5 mU/kg/min produced a 19 % and 44 % increase in adenosine-induced peak hyperemic MBF respectively. In the post-DIGAMI GIK and IIT studies the doses infused ranged between 0.2 mU/kg/min up to a maximum of 1.25 mU/kg/min. Seven of these studies had infusion rates of <1 mU/kg/min [1, 21, 22, 28, 30, 33, 34] , and two did not report their infusion rates [23, 43] . Clearly, it is possible that the hyperemic effect of insulin in myocardial ischemia may have to be above a Fig. 2 Diagram illustrating the effects of insulin on myocardial ischaemia and potential confounding factors certain value to be effective and that, for example, doses lower than 1 mU/kg/min may not be sufficient.
High Prevalence of Hypoglycemia during IIT and GIK Studies
Hypoglycaemia, which reduces MBF, occurred frequently in the treatment arms of the GIK and IIT studies and ranged from 0 to 23 % (see Tables 1 and 2 ). However, in 5 studies the rates were not mentioned at all [21, [26] [27] [28] [29] . Some studies recorded symptomatic hypoglycaemia only (not biochemical) and this would significantly underestimate true biochemical hypoglycemia [22, 25] .
Furthermore, the frequency of glucose measurements varied widely, with three studies only measuring blood glucose three times within a 24-h period and are therefore likely to have missed episodes of hypoglycemia [22, 25, 26] .
The Role of Insulin Resistance
Insulin resistance is present in patients with type 2 diabetes (T2DM) and also those patients with metabolic syndrome. The prevalence of T2DM within the ACS-related GIK and IIT trials ranged from 6 to 39 %, and was a pre-requisite for all patients participating in the DIGAMI-2 trial [32] . Central abdominal obesity (BMI >30 kg/m 2 ) which forms a major parameter of the 'prediabetes' metabolic syndrome is associated with insulin resistance [44] . Obesity was prevalent in over 23 % of patients in insulin-related ACS trials, implying that metabolic syndrome and therefore insulin resistance was also present [22, 23, 32] . In fact, a recent study identified that insulin resistance in non-diabetics was diagnosed in 60-70 % of their STEMI cohort [45] . The results of studies investigating the effect of insulin resistance on MBF have been conflicting. Quantitative assessment of MBF using PET in 167 angina patients found insulin resistance to be an independent predictor of reduced hyperaemic MBF [46] . Another study demonstrated a diminished MBF response to exogenous insulin administration in obese subjects using both physiological and supra-physiological hyperinsulinemia regimens [47] . In contrast however, Sondergaard using PET, reported no difference in hyperemic MBF between T2DM and non-diabetics with coronary artery disease, in response to hyperinsulinemia [48] . If we consider that insulin resistance does indeed impair insulin's vasodilatory effect on MBF, then this may explain at least in part the disappointing results in some of the GIK and IIT ACS studies which contained a significant number of patients with metabolic syndrome and T2DM.
The Effects of Insulin Infusion on Myocardial Ischemiawhat has Gone before and what is not Known
Human studies investigating whether an infusion of insulin (whilst maintaining normoglycemia) can improve MBF within ischemic myocardium, have been limited and inconclusive. Marano examined the effect of a GIK infusion on peak MBF but this was 24 h after a completed infarct [49] . The group showed that although there was improvement in flow, this was confined to the segments adjacent to the infarcted area. Bucciarelli-Ducci et al. administered 24-h GIK infusions on STEMI patients initiated prior to undergoing primary PCI. GIK infusion was found to be associated with improved myocardial blush grade which is used as an angiographic marker of myocardial reperfusion after PCI [50] . These two studies add further argument that timely administration of such therapies predict myocardial salvage. There have also been studies undertaken during the 1970's in patients with ischemic heart disease but these produced conflicting and unreliable results [51, 52] . In general, they used small numbers, were observational and had little or no statistical power. Furthermore, the assessment of ischemia was indirect, using symptoms, ECG and end-diastolic pressure changes. Large bolus doses of both insulin and glucose were also given which often caused transient and severe hyperglycemia (>30 mmol). This may be important because in STEMI patients, hyperglycemia is a strong predictor of impaired coronary flow prior to primary PCI [53] .
Specifically, there have been two studies, both in 2006, looking at the effects of hyperinsulinemic euglycemia on MBF in patients with ischemic heart disease [48, 54] . All subjects had stable angina with documented significant CAD, rather than ACS. Each study produced conflicting results to the other. Using vasodilator (adenosine) PET to assess MBF, Lautamaki investigated the effects of hyperinsulinemic euglycemia in 47 patients with significant CAD and T2DM [54] . Insulin was infused at 1 mU/kg/min for 60 min with the result that MBF to the ischemic regions was improved by 20 % compared to without insulin. However, the vasodilator flow assessments (with and without insulin) were performed within a single session and always in this set order: placebo infusion followed by insulin infusion. This methodological strategy could have inadvertently induced a pre-conditioning effect and reduced ischemic burden in the insulin-based arm [55] .
Sondergaard examined 27 patients with CAD, of whom 12 had T2DM [48] . She reported that hyperinsulinemic euglycemia (1 mU/kg/min infused for 2 h) had no effect on hyperaemic MBF in the ischemic regions. However they did not show increased flow in the healthy regions either, which is surprising as this feature has been consistently demonstrated in other studies.
Importantly, neither study found an increase in the area of myocardial ischemia. This 'coronary steal phenomenon' can theoretically occur when maximal vasodilatation of resistance vessels occurs in non-ischemic regions with diversion of blood away from underperfused regions where the vasodilator reserve has been exhausted [56] . This phenomenon could potentially worsen myocardial ischaemia, but it should be pointed out that insulin has not been demonstrated to elicit this response in either animal or human studies. In summary therefore, the effect of hyperinsulinemic euglycemia on patients with myocardial ischemia is not known.
Future Research
The potential confounding factors that may offset the beneficial therapeutic effects of hyperinsulinaemia during ischaemia are summarised in Fig. 2 . We recommend that any future studies should initially address these before any further large trials examining the vasodilatory effects of hyperinsulinaemia in myocardial ischemia are undertaken. Larger randomised control trials could then be designed to assess the effects of acute insulin therapy in ACS from the perspective of adjunctive reperfusion therapy.
Conclusion
Exploration of the potential benefits of insulin therapy in the context of acute coronary syndrome has been extensively studied over the last 100 years. Although the initial studies showed promise, later studies have been surprisingly disappointing in terms of clinical outcome. This may be because previous trials have been designed around the metabolic modulatory aspects of insulin, and have overlooked its potent vasodilator effect. As a result, delay in initiation of therapy, insufficient insulin dose, insulin resistance and hypoglycemia may all have had important mitigating effects in terms of outcome. We recommend detailed studies determining the optimum conditions for insulin's vasodilator effect on myocardial blood flow before any further large-scale ACS trials involving insulin are undertaken.
